Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei

被引:72
作者
Shahi, SK
Krauth-Siegel, RL
Clayton, CE
机构
[1] ZMBH, D-69120 Heidelberg, Germany
[2] BZH, D-69120 Heidelberg, Germany
关键词
D O I
10.1046/j.1365-2958.2002.02831.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Melaminophenyl arsenical drugs are a mainstay of chemotherapy against late-stage African sleeping sickness, but drug resistance is increasingly prevalent. We describe here the characterization of two genes encoding putative metal-thiol conjugate transporters from Trypanosoma brucei. The two proteins, TbMRPA and TbMRPE, were each overexpressed in trypanosomes, with or without co-expression of two key enzymes in trypanothione biosynthesis, ornithine decarboxylase and gamma-glutamyl-cysteine synthetase. Overexpression of gamma-glutamyl-cysteine synthetase resulted in a twofold increase in cellular trypanothione, whereas overexpression of ornithine decarboxylase had no effect on the trypanothione level. The overexpression of TbMRPA resulted in a 10-fold increase in the IC50 of melarsoprol. The overexpression of the trypanothione biosynthetic enzymes alone gave two- to fourfold melarsoprol resistance, but did not enhance resistance caused by MRPA. Overexpression of TbMRPE had little effect on susceptibility to melarsoprol but did give two- to threefold resistance to suramin.
引用
收藏
页码:1129 / 1138
页数:10
相关论文
共 36 条
[1]   The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes [J].
Barrett, MP ;
Fairlamb, AH .
PARASITOLOGY TODAY, 1999, 15 (04) :136-140
[2]   Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei [J].
Biebinger, S ;
Wirtz, LE ;
Lorenz, P ;
Clayton, C .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1997, 85 (01) :99-112
[3]   Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis [J].
Blum, J ;
Nkunku, S ;
Burri, C .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (05) :390-400
[4]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[5]   Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment [J].
Burri, C ;
Keiser, J .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (05) :412-420
[6]   MECHANISM OF INHIBITION OF TRYPANOTHIONE REDUCTASE AND GLUTATHIONE-REDUCTASE BY TRIVALENT ORGANIC ARSENICALS [J].
CUNNINGHAM, ML ;
ZVELEBIL, MJJM ;
FAIRLAMB, AH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 221 (01) :285-295
[7]   DNA AMPLIFICATION IN ARSENITE-RESISTANT LEISHMANIA [J].
DETKE, S ;
KATAKURA, K ;
CHANG, KP .
EXPERIMENTAL CELL RESEARCH, 1989, 180 (01) :161-170
[8]   Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes [J].
Ephros, M ;
Bitnun, A ;
Shaked, P ;
Waldman, E ;
Zilberstein, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :278-282
[9]  
FAHEY RC, 1987, METHOD ENZYMOL, V143, P85
[10]   INVIVO EFFECTS OF DIFLUOROMETHYLORNITHINE ON TRYPANOTHIONE AND POLYAMINE LEVELS IN BLOOD-STREAM FORMS OF TRYPANOSOMA-BRUCEI [J].
FAIRLAMB, AH ;
HENDERSON, GB ;
BACCHI, CJ ;
CERAMI, A .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1987, 24 (02) :185-191